Successful treatment of high-risk gestational trophoblastic disease in a patient with intolerance to standard chemotherapy (clinical case)-Reference-Cited by-同舟云学术

Successful treatment of high-risk gestational trophoblastic disease in a patient with intolerance to standard chemotherapy (clinical case)

Published:2021-01-12 Issue:3 Volume:16 Page:67-71
ISSN:1999-8627
Container-title:Tumors of female reproductive system
language:
Short-container-title:Opuholi ženskoj reproduktivnoj sistemy

Author:

Teletaeva G. M.¹,Ulrikh E. A.²,Latipova D. Kh.¹,Semenova A. I.¹,Levchenko E. V.³,Ulrikh D. G.⁴,Berlev I. V.³^ORCID,Semiglazova T. Yu.³,Protsenko S. A.¹,Urmancheeva A. F.³

Affiliation:

1. N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia

2. N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia; I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia; V.A. Almazov National Medical Research Center, Ministry of Health of Russia

3. N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia; I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia

4. Saint Petersburg State Pediatric Medical University

Abstract

Gestational trophoblastic disease is a rare tumor highly sensitive to systemic drug therapy. The standard regimens of chemotherapy of I and II lines for patients in the high-risk group for gestational trophoblastic disease are the EMA-CO, EMA-EP and TP/TE regimens, which have been demonstrated to be effective and require adherence to drug doses and intervals of administration. If these criteria are not met, the risk of developing resistance with an unfavorable outcome for patients is extremely high. The situation is extremely difficult when a patient has an absolute allergic intolerance to one of the components of standard regimens, which is presented in a clinical case.

Publisher

Publishing House ABV Press

Subject

Pharmacology (medical),Obstetrics and Gynecology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference6 articles.

1. Kaur B., Short D., Fisher R.A. et al. Atypical placental site nodule (APSN) and association with malignant gestational trophoblastic disease; a clinicopathologic study of 21 cases. Int J Gynecol Pathol 2015;34(2):152–8.

2. Ning F., Hou H., Morse A.N., Lash G.E. Understanding and management of gestational trophoblastic disease. F1000Res 2019;8(F1000Faculty Rev):428. DOI: 10.12688/f1000research.14953.1.

3. Banerjee D., Barsode S.D., Basu P. Management of gestational trophoblastic diseases – an update. Rev Recent Clin Trials 2015;10(4):255–62.

4. Ngan H.Y.S., Seckl M.J., Berkowitz R.S. et al. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynaecol Obstet 2018;143(Suppl 2):79–85.

5. Veras E., Kurman R.J., Wang T.-L., Shih I.-M. PD-L1 expression in human placentas and gestational trophoblastic diseases. Int J Gynecol Pathol 2017;36:146–53. DOI: 10.1097/PGP.0000000000000305.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trophoblastic neoplasia on the background of developing pregnancy: a rare gynecological tumor with a chance of favorable outcome for mother and fetus;Tumors of female reproductive system;2022-12-02

2. Malignant trophoblastic disease: a rare tumor requiring personalized treatment. Stateof-the-art;Russian Journal for Personalized Medicine;2022-09-16